• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病患者的肠道微生物群。

Intestinal microbiota in patients with nonalcoholic fatty liver disease.

机构信息

Department of Pediatrics, Hospital for Sick Children, Toronto, Canada.

出版信息

Hepatology. 2013 Jul;58(1):120-7. doi: 10.1002/hep.26319. Epub 2013 May 14.

DOI:10.1002/hep.26319
PMID:23401313
Abstract

UNLABELLED

Despite evidence that the intestinal microbiota (IM) is involved in the pathogenesis of obesity, the IM composition of patients with nonalcoholic fatty liver disease (NAFLD) has not been well characterized. This prospective, cross-sectional study was aimed at identifying differences in IM between adults with biopsy-proven NAFLD (simple steatosis [SS] or nonalcoholic steatohepatitis [NASH]) and living liver donors as healthy controls (HC). Fifty subjects were included: 11 SS, 22 NASH, and 17 HC. One stool sample was collected from each participant. Quantitative real-time polymerase chain reaction was used to measure total bacterial counts, Bacteroides/Prevotella (herein referred to as Bacteroidetes), Clostridium leptum, C. coccoides, bifidobacteria, Escherichia coli and Archaea in stool. Clinical and laboratory data, food records, and activity logs were collected. Patients with NASH had a lower percentage of Bacteroidetes (Bacteroidetes to total bacteria counts) compared to both SS and HC (P = 0.006) and higher fecal C. coccoides compared to those with SS (P = 0.04). There were no differences in the remaining microorganisms. As body mass index (BMI) and dietary fat intake differed between the groups (P < 0.05), we performed linear regression adjusting for these variables. The difference in C. coccoides was no longer significant after adjusting for BMI and fat intake. However, there continued to be a significant association between the presence of NASH and lower percentage Bacteroidetes even after adjusting for these variables (P = 0.002; 95% confidence interval = -0.06 to -0.02).

CONCLUSION

There is an inverse and diet-/BMI-independent association between the presence of NASH and percentage Bacteroidetes in the stool, suggesting that the IM may play a role in the development of NAFLD.

摘要

目的

尽管有证据表明肠道微生物群(IM)参与了肥胖症的发病机制,但非酒精性脂肪性肝病(NAFLD)患者的 IM 组成尚未得到很好的描述。本前瞻性、横断面研究旨在鉴定活检证实的 NAFLD(单纯性脂肪变性[SS]或非酒精性脂肪性肝炎[NASH])患者与作为健康对照(HC)的活体供肝者之间 IM 的差异。

方法

纳入 50 名参与者:11 名 SS,22 名 NASH 和 17 名 HC。从每位参与者收集一份粪便样本。使用定量实时聚合酶链反应测量粪便中总细菌计数、拟杆菌/普雷沃氏菌(以下简称拟杆菌门)、梭状芽胞杆菌、C. coccoides、双歧杆菌、大肠杆菌和古菌。收集临床和实验室数据、饮食记录和活动日志。

结果

与 SS 和 HC 相比,NASH 患者的拟杆菌门(拟杆菌门与总细菌计数的比值)百分比较低(P = 0.006),粪便 C. coccoides 较高(P = 0.04)。其余微生物无差异。由于各组之间的体重指数(BMI)和膳食脂肪摄入量不同(P < 0.05),我们进行了线性回归分析,调整了这些变量。调整 BMI 和脂肪摄入量后,C. coccoides 的差异不再显著。然而,即使在调整这些变量后,NASH 的存在与拟杆菌门百分比降低之间仍存在显著关联(P = 0.002;95%置信区间=-0.06 至-0.02)。

结论

NASH 的存在与粪便中拟杆菌门的百分比之间存在负相关且与饮食/ BMI 无关,提示 IM 可能在 NAFLD 的发生发展中起作用。

相似文献

1
Intestinal microbiota in patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者的肠道微生物群。
Hepatology. 2013 Jul;58(1):120-7. doi: 10.1002/hep.26319. Epub 2013 May 14.
2
A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls.一项横断面研究评估了加拿大非酒精性脂肪性肝病患者与健康对照者的饮食摄入和体力活动。
J Acad Nutr Diet. 2014 Aug;114(8):1181-94. doi: 10.1016/j.jand.2014.01.009. Epub 2014 Mar 14.
3
Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance.非酒精性脂肪性肝病与肠道菌群失调有关,而与体重指数和胰岛素抵抗无关。
Sci Rep. 2018 Jan 23;8(1):1466. doi: 10.1038/s41598-018-19753-9.
4
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的胆汁酸与肠道菌群失调
PLoS One. 2016 May 20;11(5):e0151829. doi: 10.1371/journal.pone.0151829. eCollection 2016.
5
Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.非酒精性脂肪性肝炎(NASH)患者肠道微生物组的特征:内源性酒精与 NASH 之间的联系。
Hepatology. 2013 Feb;57(2):601-9. doi: 10.1002/hep.26093. Epub 2013 Jan 8.
6
Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.经肝活检证实的非酒精性脂肪性肝病患者与健康受试者的血浆磷脂和脂肪酸组成存在差异。
Nutr Diabetes. 2016 Jul 18;6(7):e220. doi: 10.1038/nutd.2016.27.
7
Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.台湾经活检证实的非酒精性脂肪性肝病患者的肠道微生物失调:一项横断面研究。
Nutrients. 2020 Mar 19;12(3):820. doi: 10.3390/nu12030820.
8
Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.非酒精性脂肪性肝炎与脂肪变性:脂肪组织胰岛素抵抗和对脂肪摄入的反应异常可预测肝损伤以及糖和脂蛋白代谢的改变。
Hepatology. 2012 Sep;56(3):933-42. doi: 10.1002/hep.25739. Epub 2012 Jul 3.
9
Helicobacter pylori infection in patients with nonalcoholic fatty liver disease.幽门螺杆菌感染与非酒精性脂肪性肝病。
Metabolism. 2013 Jan;62(1):121-6. doi: 10.1016/j.metabol.2012.06.007. Epub 2012 Jul 27.
10
Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).预测非酒精性脂肪性肝病(NAFLD)患者非酒精性脂肪性肝炎(NASH)的因素。
J Gastrointestin Liver Dis. 2011 Jun;20(2):153-9.

引用本文的文献

1
infection and association with chronic diseases: A focus on cardiovascular disease, MASLD, and type 2 diabetes.感染与慢性病的关联:聚焦心血管疾病、代谢功能障碍相关脂肪性肝病和2型糖尿病。
Metabol Open. 2025 Aug 11;27:100385. doi: 10.1016/j.metop.2025.100385. eCollection 2025 Sep.
2
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病(MASLD):肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
3
Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.
代谢功能障碍相关脂肪性肝病:心血管风险的隐匿驱动因素及新的干预靶点
Int J Mol Sci. 2025 Aug 21;26(16):8081. doi: 10.3390/ijms26168081.
4
Citrus Pectin Supplementation Alleviated Hepatic Lipid Accumulation through Gut Microbiota Indole Lactic Acid Promoting Hepatic Bile Acid Synthesis and Excretion.补充柑橘果胶通过肠道微生物群吲哚乳酸促进肝脏胆汁酸合成与排泄减轻肝脏脂质积累。
Int J Biol Sci. 2025 Jul 28;21(11):5015-5033. doi: 10.7150/ijbs.116929. eCollection 2025.
5
Development and validation of a multimodal model integrating gut microbiota and metabolite for identifying sarcopenia in patients with MASLD: a study from two centers in China.整合肠道微生物群和代谢物的多模态模型用于识别非酒精性脂肪性肝病患者肌肉减少症的开发与验证:一项来自中国两个中心的研究
Nutr J. 2025 Aug 22;24(1):129. doi: 10.1186/s12937-025-01198-2.
6
Gut microbiota-derived metabolite trimethylamine N-oxide alters the host epigenome through inhibition of S-adenosylhomocysteine hydrolase.肠道微生物群衍生的代谢产物氧化三甲胺通过抑制S-腺苷同型半胱氨酸水解酶改变宿主表观基因组。
J Biol Chem. 2025 Jul 25;301(9):110521. doi: 10.1016/j.jbc.2025.110521.
7
Genetic evidence for causal links between diet, gut microbiota, and hepatobiliary cancer: a Mendelian randomization study.饮食、肠道微生物群与肝胆癌之间因果关系的遗传证据:一项孟德尔随机化研究。
AMB Express. 2025 Jul 4;15(1):100. doi: 10.1186/s13568-025-01910-9.
8
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.非酒精性脂肪性肝病中的肠道微生物群:病理生理学、诊断与治疗
World J Hepatol. 2025 Jun 27;17(6):106849. doi: 10.4254/wjh.v17.i6.106849.
9
Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease.多组学分析揭示代谢功能障碍相关脂肪性肝病中的跨界肠道生态失调。
Nat Metab. 2025 Jul 2. doi: 10.1038/s42255-025-01318-6.
10
Disruption of small intestinal mucosal homeostasis in mice with amiodarone induced steatohepatitis.胺碘酮诱导的脂肪性肝炎小鼠小肠黏膜稳态的破坏。
Sci Rep. 2025 Jul 2;15(1):23132. doi: 10.1038/s41598-025-04680-3.